More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often including vitamin supplements and drugs used to manage symptoms such as muscle stiffness, pain, and mental health issues — to treat their MS. That’s according to a real-world study in Canada, which also found that one…
New research project to explore how women with MS experience menopause
A new study being funded by the National Multiple Sclerosis Society (NMSS) will seek to better understand how women with multiple sclerosis (MS) navigate menopause and develop resources to address gaps in care. The study, “The Menopausal Transition, MS Symptom Management, and Multidisciplinary Care Gaps,” will use input from patients and healthcare providers and be conducted…
MS progression is unpredictable, but I’m learning to adapt
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series. It sounded like a distant storm…
Limited Ozanimod Rebound after stopping
Tweet Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. Gold R, Selmaj KW, Berkovich R, Cohen JA, Comi G, Havrdová EK, Sheffield JK, Desai H, Cheng CY, Riolo JV, Thorpe A, DeBoer E, Cree BAC.Ann Clin Transl Neurol. 2026 Mar 27. doi: 10.1002/acn3.70366. Online ahead of print Objective: Return of disease activity is expected when…
Lucid-MS moves toward clinical trial in US that will enroll MS patients
Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims to slow myelin loss — which ultimately results in the neurological problems that drive multiple sclerosis (MS) — in people with the progressive disease. The company said it expects to submit an…
With MS, movement can be one of the greatest teachers
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
Learning to advocate for myself helped me to help others with MS
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
MSBase says keep going with CD20-depletion
Tweet Zanghì A, Spelman T, Fabis-Pedrini M, Carroll WM, Butzkueven H, Kermode AG, Lechner-Scott J, van der Walt A, D’Amico E. Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase. Curr Neuropharmacol. 2026 Mar 24. doi: 10.2174/011570159X448901251228053318. Introduction: Ocrelizumab (OCR), a CD20+ B-cell depleting monoclonal antibody, is a highly effective therapy for Multiple…
In life with MS, we are in this fight together
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
Switching Natalizumab to Biosimilar
Tweet Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO. Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. BMJ Neurol Open. 2026 Mar 18;8(1):e001477. doi: 10.1136/bmjno-2025-001477. Background: In January 2024, all people with…